Terms: = Lung cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p
266 results:
1. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract] [Full Text] [Related]
2. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S355-S367. PubMed ID: 38277316
[TBL] [Abstract] [Full Text] [Related]
3. Cu(II) flavonoids as potential photochemotherapeutic agents.
Das N; Bora B; Upadhyay A; Das D; Bera A; Goswami TK
Dalton Trans; 2024 Feb; 53(7):3316-3329. PubMed ID: 38260975
[TBL] [Abstract] [Full Text] [Related]
4. Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for cancer Immunotherapy.
Geng Q; Jiao P
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257366
[TBL] [Abstract] [Full Text] [Related]
5. Single-cell immunophenotyping revealed the association of CD4+ central and CD4+ effector memory T cells linking exacerbating chronic obstructive pulmonary disease and NSCLC.
Gémes N; Balog JÁ; Neuperger P; Schlegl E; Barta I; Fillinger J; Antus B; Zvara Á; Hegedűs Z; Czimmerer Z; Manczinger M; Balogh GM; Tóvári J; Puskás LG; Szebeni GJ
Front Immunol; 2023; 14():1297577. PubMed ID: 38187374
[TBL] [Abstract] [Full Text] [Related]
6. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
[TBL] [Abstract] [Full Text] [Related]
7. A novel necroptosis signature for predicting survival in lung adenocarcinoma.
Zang K; Wang M; Zhu X; Yao B; Huang Y
BMC Med Genomics; 2023 Nov; 16(1):305. PubMed ID: 38017445
[TBL] [Abstract] [Full Text] [Related]
8. [Relationship between PD-L1 expression and tumor stem cell marker CD44 as a promising basis for the development of new approaches to cancer targeted therapy].
Sotnikova TN; Polushkina TV; Danilova NV
Arkh Patol; 2023; 85(6):70-75. PubMed ID: 38010641
[TBL] [Abstract] [Full Text] [Related]
9. IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells.
Nawas AF; Solmonson A; Gao B; DeBerardinis RJ; Minna JD; Conacci-Sorrell M; Mendelson CR
Cell Commun Signal; 2023 Nov; 21(1):331. PubMed ID: 37985999
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell lung cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Dhamelincourt E; Descourt R; Rousseau-Bussac G; Doubre H; Decroisette C; Demontrond P; Le Garff G; Falchero L; Huchot E; Vieillot S; Corre R; Kazulinski L; Bizieux A; Bigay-Gamé L; Morel H; Molinier O; Chouaïd C; Guisier F
Target Oncol; 2023 Nov; 18(6):905-914. PubMed ID: 37966566
[TBL] [Abstract] [Full Text] [Related]
11. Construction and preclinical evaluation of a zirconium-89 labelled monoclonal antibody targeting PD-L2 in lung cancer.
Yao Y; Ren Y; Hou X; Zhu J; Ma X; Liu S; Liu T; Zhang Q; Ma X; Yang Z; Zhu H; Li N
Biomed Pharmacother; 2023 Dec; 168():115602. PubMed ID: 37852097
[TBL] [Abstract] [Full Text] [Related]
12. Feasibility analysis of low-dose CT with asynchronous quantitative computed tomography to assess vBMD.
Hu T; Yang X; Gao L; Liu Y; Zhang W; Wang Y; Zhu X; Liu X; Liu H; Ma X
BMC Med Imaging; 2023 Oct; 23(1):149. PubMed ID: 37803293
[TBL] [Abstract] [Full Text] [Related]
13. STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis.
Zhang WD; Hu DM; Shi ZE; Wang QX; Zhang MY; Liu JY; Ji XL; Qu YQ
Int J Med Sci; 2023; 20(11):1427-1447. PubMed ID: 37790851
[No Abstract] [Full Text] [Related]
14. Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell lung cancer.
Zhao Y; Wang Z; Shi X; Liu T; Yu W; Ren X; Zhao H
Technol Cancer Res Treat; 2023; 22():15330338231202307. PubMed ID: 37728201
[No Abstract] [Full Text] [Related]
15. Intra-frame motion deterioration effects and deep-learning-based compensation in MR-guided radiotherapy.
Sui Z; Palaniappan P; Brenner J; Paganelli C; Kurz C; Landry G; Riboldi M
Med Phys; 2024 Mar; 51(3):1899-1917. PubMed ID: 37665948
[TBL] [Abstract] [Full Text] [Related]
16. Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults.
Stiefel J; Kushner BH; Roberts SS; Iglesias-Cardenas F; Kramer K; Modak S
JCO Precis Oncol; 2023 Aug; 7():e2300138. PubMed ID: 37561984
[TBL] [Abstract] [Full Text] [Related]
17. PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma.
Matsubara E; Shinchi Y; Komohara Y; Yano H; Pan C; Fujiwara Y; Ikeda K; Suzuki M
Med Mol Morphol; 2023 Dec; 56(4):250-256. PubMed ID: 37402054
[TBL] [Abstract] [Full Text] [Related]
18. PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell lung cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F; Redrado M; Houry M; Hastings K; Molero-Abraham M; Lozano T; Solorzano JL; Sanz-Ortega J; Adradas V; Amat R; Redin E; Leon S; Legarra N; Garcia J; Serrano D; Valencia K; Robles-Oteiza C; Foggetti G; Otegui N; Felip E; Lasarte JJ; Paz-Ares L; Zugazagoitia J; Politi K; Montuenga L; Calvo A
Cancer Res; 2023 Aug; 83(15):2513-2526. PubMed ID: 37311042
[TBL] [Abstract] [Full Text] [Related]
19. Pre-existing tumor host immunity characterization in resected non-small cell lung cancer.
Rocha P; Rodrigo M; Moliner L; Menendez S; Masfarré L; Navarro N; Del Rey-Vergara R; Galindo-Campos M; Taus Á; Giner M; Sanchez I; Rodríguez-Fuster A; Aguiló R; Chalela R; Sánchez-Font A; Belda J; Curull V; Pijuan L; Casadevall D; Clavé S; Bellosillo B; Perera-Bel J; Comerma L; Arriola E
Lung Cancer; 2023 Jul; 181():107257. PubMed ID: 37263182
[TBL] [Abstract] [Full Text] [Related]
20. Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.
Raza A; Mohsen R; Kanbour A; Zar Gul AR; Philip A; Vijayakumar S; Hydrose S; Prabhu KS; Al-Suwaidi AK; Inchakalody VP; Merhi M; Abo El-Ella DM; Tauro MA; Akbar S; Al-Bozom I; Abualainin W; Al-Abdulla R; Sirriya SA; Hassnad S; Uddin S; Mohamed Ibrahim MI; Al Homsi U; Demime S
Front Immunol; 2023; 14():1157100. PubMed ID: 37256148
[TBL] [Abstract] [Full Text] [Related]
[Next]
